Edap Tms Financial Results
EDAP TMS (FocalTherics) reported Q3 2026 revenue of $9.8 million, a 26% increase year-over-year, driven by a 32% increase in U.S. procedure volume and seven Focal One system sales. The company narrowed its full-year 2026 revenue guidance to $50.0-$52.0 million, representing 34% to 39% growth over 2025.
- Term
- Q3 2026
“We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France. U.S. procedure volumes accelerated year-over-year to 32% for the third quarter of 2026, compared to 15% in 2025. Driven by our sustained commercial traction, accelerating technology adoption, and our focus on our HIFU opportunity, we remain highly confident in our growth strategy and on the opportunity ahead as we close out the year.”
Ryan Rhodes, CEO of FocalTherics